Welcome to our dedicated page for INSMED SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
INSMED Inc (INSM) director David R. Brennan reported selling 25,000 shares of common stock on September 9, 2026 in a sale described as an open market or private transaction at $124.00 per share. Following this sale, he directly holds 39,238 shares of INSMED common stock.
The filing also reports indirect ownership of 60,000 shares held through a spouse revocable trust as of the same date. No Rule 10b5-1 trading plan is reported for these transactions.
INSMED Inc (INSM) is the issuer for a notice by director David R. Brennan covering a proposed sale of up to 25,000 shares of common stock under Rule 144. The shares are held in an account at Wells Fargo Clearing Services for the Revocable Trust of David R. Brennan, for which he serves as trustee.
The shares relate to equity grants from the issuer dated May 22, 2024, May 15, 2025, and May 22, 2026, and are listed with an aggregate market value of 3,099,729.14 as of a proposed sale date of September 9, 2026 on Nasdaq. The notice is dated September 10, 2026 and is a required disclosure before the potential sale.
INSMED Inc (INSM) director Melvin Sharoky, MD reported an indirect sale of 5,000 shares of common stock on 2026-08-17 through Padonia, LLC at a weighted average price of $127.53 per share, within a range of $127.51–$127.61. After this transaction Padonia, LLC held zero shares. Dr. Sharoky continues to hold 246,081 shares directly, and additional shares are held indirectly through his spouse and several UTMA/FL custodial accounts for family members, for which he serves as custodian.
Padonia LLC, associated with Melvin Sharoky, filed a Form 144 notice for a proposed sale of up to 5,000 shares of Insmed Inc. common stock on NASDAQ. The filing lists an approximate aggregate market value of $637,636.84 for these shares and references 218,381,503 as an identifying security number. The filing also notes that 10,000 shares of common stock were previously purchased for cash in an open-market transaction on May 15, 2023, with settlement on May 17, 2023.
Darwin Global Management, Ltd., together with its Chief Investment Officer Dr. Abhishek Trehan and Darwin Global Master Fund Ltd., reports beneficial ownership of Insmed Inc. common stock. The group reports 6,431,163 shares of common stock, representing 3.0% of the class, based on 216,752,451 shares outstanding as of May 1, 2026. Voting and dispositive power over these shares is reported on a shared basis, with no sole voting or dispositive power, and the filing states that the reporting persons are the beneficial owners for Section 13 purposes only as described.
INSMED Inc Chief Operating Officer Roger Adsett reported multiple option exercises and a same‑day share sale. He exercised three stock option grants covering a total of 239,850 shares of common stock at exercise prices of $13.67, $17.16, and $30.46 per share, with the options fully vested under a stated vesting schedule. He then sold 239,850 shares of common stock at a weighted average price of $133.27 per share, within a price range of $133.00–$133.51. One acquisition line also notes inclusion of 141 shares from the company’s 2018 Employee Stock Purchase Plan.
INSM has a notice indicating potential sales of common stock. The filing lists 239,850 common shares in the section on securities to be sold, with trading referenced on NASDAQ and an indicated date of August 10, 2026. The form also reports prior sales over the past three months by Roger Adsett, including transactions involving 2,370 and 5,837 common shares on June 3, 2026 and May 13, 2026, respectively. Additional figures such as 31,963,198 and 218,381,503 are reported in connection with the common stock.
Insmed Inc’s Chief Medical Officer, Martina Flammer, exercised stock options for 27,173 shares of common stock on August 6, 2026 and sold the same number of shares, in transactions effected under a Rule 10b5-1 trading plan adopted on February 27, 2025.
The options covered 18,278 shares at $18.95 and 8,895 shares at $25.83. Related sales were 8,895 shares at $127.00 and 18,278 shares at a weighted average $129.40 within a $129.40–$129.41 range.
Reporting person Martina Flammer has filed to sell up to 27,173 shares of common stock, to be executed through Merrill Lynch, with an approximate sale date of 08/06/2026. The issuer reports 218,381,503 shares outstanding as of that date.
The sale relates to stock plan activity. Over the past three months, Flammer has reported several open-market sales of common shares between May and July 2026, each disclosing the number of shares and corresponding dollar amounts.
FMR LLC filed an amended Schedule 13G reporting beneficial ownership of 16,127,583.08 shares of INSMED INC common stock, representing 7.4% of the class (CUSIP 457669307). FMR LLC reports sole dispositive power over all 16,127,583.08 shares and sole voting power over 15,133,671.95 shares, with no shared voting or dispositive power.
Abigail P. Johnson is also reported as having beneficial ownership and sole dispositive power over the same 16,127,583.08 shares, representing 7.4% of the common stock, but with no sole or shared voting power. One or more other persons have the right to receive dividends or proceeds from these shares, but no single such person has more than five percent of INSMED INC’s outstanding common stock.